Sulodexide Therapy for the Treatment of Diabetic Retinopathy.
Wydanie 3/2022
str. 43 – 45
Autorzy: Michał Post1,2, Dorota Polakowska1, Karolina Bonińska2,3, Jacek P. Szaflik1,4,5.
- Samodzielny Publiczny Kliniczny Szpital Okulistyczny w Warszawie.
- Klub 40, Polskie Towarzystwo Okulistyczne.
- Klinika Diagnostyki i Mikrochirurgii Jaskry Uniwersytetu Medycznego w Lublinie.
Kierownik: prof. dr hab. n. med. Tomasz Żarnowski. - Katedra i Klinika Okulistyki Wydziału Lekarskiego Warszawskiego Uniwersytetu Medycznego.
Kierownik: prof. dr hab. n. med. Jacek P. Szaflik. - Centrum Mikrochirurgii Oka „Laser” w Warszawie.
Summary:
Diabetes mellitus is causing dysfunction of the vascular endothelial cells, which results in various pathologies within the microvascular and macrovascular system including retinopathy, neuropathy, nephropathy, and angiopathy. Endothelial dysfunction is caused by hyperglycemia via diferent mechanisms, such as damage to the glycocalyx, activation of the inflammation, oxidative stress, stimulation of cellular senescence, induction of imbalance between coagulation and fibrinolysis. Many studies suggests that inhibition of retinal endothelial dysfunction may be an efective way of slowing the progress of diabetic retinopathy. Sulodexide (glycosaminoglycans composed from heparin-like and dermatan fractions) is associated with a protective and regenerating action on the glycocalyx, slows down senescence of human venous and arterial endothelial cells. Moreover its mechanism of action invloves an anti-inflammatory, anti-proteolytic, and antioxidant effect, including interference with metabolic and non-metabolic stress. In present study sulodexide was chosen to evaluate its therapeutic properties for the treatment of diabetic retinopathy.